![Simon Lu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Simon Lu
Director/Board Member at
ASCENTAGE PHARMA GROUP INTERNATIONAL
Net worth: 208 750 $ as of 30/08/2026
Profile
Dr. Simon D.
Lu is on the Board of Directors at Ascentage Pharma Group International Co., Ltd. Dr. Lu was previously employed as a Managing Director by CEL Partners Co. Ltd., a Partner & Investment Manager by NewMargin Ventures Co. Ltd., and an Auditor by Arthur Andersen Business Consulting Co. Ltd. (Shanghai).
He also served on the board at McGill University.
He received his undergraduate degree from Nankai University and a doctorate degree from Nankai University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 19/04/2026 | 48,937 ( 0.01% ) | 208 750 $ | 30/08/2026 |
Simon Lu active positions
| Companies | Position | Start |
|---|---|---|
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Director/Board Member | 05/07/2018 |
Former positions of Simon Lu
| Companies | Position | End |
|---|---|---|
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Director/Board Member | 31/10/2018 |
CEL Partners Co. Ltd.
 CEL Partners Co. Ltd. Investment ManagersFinance CEL Partners is an active manager which invests in medium-sized Chinese companies in growing and government-promoted sectors where CEL brings strong industry expertise including environmental (renewable energy, clean transport, energy efficiency, waste recovery , water treatment), healthcare (medical supplies & equipment, OTC/TCM drugs, distribution, CRO services), agribusiness (agriculture machinery, fresh food, green/bio products, logistics/cold-chain/food safety), consumer (FMCG, specialized retail, luxury products, household appliances housing materials and furniture) and suppliers (specialized suppliers such as automotive and aerospace suppliers, automotive parts and services). The firm seeks to invest USD 4-15 million in fast-growing Chinese companies with sales of USD 20-150 million, in Chinese SMEs with development or acquisition plans in Europe and in European SMEs with strong development plans in China. CEL Partners takes minority stakes in their investee companies. They exit investments through trade sales and IPOs. | Chief Executive Officer | 30/06/2009 |
Shanghai NewMargin Ventures Investment Management Co. Ltd.
 Shanghai NewMargin Ventures Investment Management Co. Ltd. Investment ManagersFinance NewMargin is a hands-on, value added manager which invests in high-growth China-based companies in a range of industrial sectors including information technology, healthcare and life sciences, and new material and environmental protection. The firm seeks to invest well managed companies, partnering with entrepreneurs early, sharing their expertise and helping them to execute their business strategies. They provide their investee companies with access to their network of industry experts, entrepreneurs, executives, professional service providers and venture capital funds throughout the world and seek exits in the form of IPOs and trade sales. | Chief Investment Officer | 30/11/2007 |
Arthur Andersen Business Consulting Co. Ltd. (Shanghai) | Comptroller/Controller/Auditor | - |
Training of Simon Lu
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
86
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shanghai NewMargin Ventures Investment Management Co. Ltd.
Shanghai NewMargin Ventures Investment Management Co. Ltd. Investment ManagersFinance NewMargin is a hands-on, value added manager which invests in high-growth China-based companies in a range of industrial sectors including information technology, healthcare and life sciences, and new material and environmental protection. The firm seeks to invest well managed companies, partnering with entrepreneurs early, sharing their expertise and helping them to execute their business strategies. They provide their investee companies with access to their network of industry experts, entrepreneurs, executives, professional service providers and venture capital funds throughout the world and seek exits in the form of IPOs and trade sales. | Finance |
Nankai University
 Nankai University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CEL Partners Co. Ltd.
CEL Partners Co. Ltd. Investment ManagersFinance CEL Partners is an active manager which invests in medium-sized Chinese companies in growing and government-promoted sectors where CEL brings strong industry expertise including environmental (renewable energy, clean transport, energy efficiency, waste recovery , water treatment), healthcare (medical supplies & equipment, OTC/TCM drugs, distribution, CRO services), agribusiness (agriculture machinery, fresh food, green/bio products, logistics/cold-chain/food safety), consumer (FMCG, specialized retail, luxury products, household appliances housing materials and furniture) and suppliers (specialized suppliers such as automotive and aerospace suppliers, automotive parts and services). The firm seeks to invest USD 4-15 million in fast-growing Chinese companies with sales of USD 20-150 million, in Chinese SMEs with development or acquisition plans in Europe and in European SMEs with strong development plans in China. CEL Partners takes minority stakes in their investee companies. They exit investments through trade sales and IPOs. | Finance |
Arthur Andersen Business Consulting Co. Ltd. (Shanghai) | |
Ascentage Pharma Group International Co., Ltd.
 Ascentage Pharma Group International Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in discovering, developing and commercializing of therapies for hematological malignancies | Health Technology |
- Stock Market
- Insiders
- Simon Lu
